In the last few years, a great interest has emerged in investigating the pleiotropic effects of Glucagon Like Peptide-1 Receptor Agonists (GLP-1RAs). While GLP-1RAs ability to lower plasma glucose and to induce weight loss has allowed them to be approved for the treatment of diabetes and obesity, consistent evidences from in vitro studies and preclinical models suggested that GLP-1RAs have anti-inflammatory properties and that may modulate the immune-system. Notably, such anti-inflammatory effects target different pathways in different tissues, underling the broad spectrum of GLP-1RAs actions. This review examines some of the currently proposed molecular mechanisms of GLP-1RAs actions and explores their potential benefits in reducing inflammatory responses, which may well suggest a future therapeutic use of GLP-1RAs in new indications.

The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists / G. Bendotti, L. Montefusco, M.E. Lunati, V. Usuelli, I. Pastore, E. Lazzaroni, E. Assi, A.J. Seelam, B. El Essawy, J. Jang, C. Loretelli, F. D'Addio, C. Berra, M. Ben Nasr, G. Zuccotti, P. Fiorina. - In: PHARMACOLOGICAL RESEARCH. - ISSN 1096-1186. - 182:(2022 Aug), pp. 106320.1-106320.7. [10.1016/j.phrs.2022.106320]

The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists

L. Montefusco
Co-primo
;
M.E. Lunati;V. Usuelli;E. Lazzaroni;E. Assi;A.J. Seelam;C. Loretelli;F. D'Addio;M. Ben Nasr;P. Fiorina
Ultimo
2022

Abstract

In the last few years, a great interest has emerged in investigating the pleiotropic effects of Glucagon Like Peptide-1 Receptor Agonists (GLP-1RAs). While GLP-1RAs ability to lower plasma glucose and to induce weight loss has allowed them to be approved for the treatment of diabetes and obesity, consistent evidences from in vitro studies and preclinical models suggested that GLP-1RAs have anti-inflammatory properties and that may modulate the immune-system. Notably, such anti-inflammatory effects target different pathways in different tissues, underling the broad spectrum of GLP-1RAs actions. This review examines some of the currently proposed molecular mechanisms of GLP-1RAs actions and explores their potential benefits in reducing inflammatory responses, which may well suggest a future therapeutic use of GLP-1RAs in new indications.
Glucagon-like peptide 1;Inflammation;Immune system; Lymphocytes; Macrophages; Exenatide (PubChem CID: 45588096); Glucagon-like peptide 1; Immune system; Inflammation; Liraglutide (PubChem CID: 16134956); Lymphocytes; Macrophages; Semaglutide (PubChem CID: 56843331)
Settore MED/13 - Endocrinologia
Settore MED/50 - Scienze Tecniche Mediche Applicate
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1043661822002651-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.13 MB
Formato Adobe PDF
1.13 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/934646
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact